N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-6-(2-morpholinoethyl)nicotinamide | 1401711-70-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-6-(2-morpholinoethyl)nicotinamide
• 英文别名: N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-6-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
• CAS: 1401711-70-3
• 化学式: C₃₆H₅₂N₄O₃
• 分子量: 588.834
• InChiKey: JITSUJFMLTYBBU-KUBAVDMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  43
• 可旋转键数：
  21
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• FATTY ACID NON-FLUSHING NIACIN DERIVATIVES AND THEIR USES
  申请人：Vu Chi B.

  公开号：US20120252810A1

  公开（公告）日：2012-10-04

  The invention relates to fatty non-flushing acid niacin derivatives; compositions comprising an effective amount of a fatty acid non-flushing niacin derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid non-flushing niacin derivative.

  这项发明涉及脂肪非潮红酸烟酸衍生物；包含有效量脂肪酸非潮红烟酸衍生物的组合物；以及治疗或预防代谢性疾病的方法，包括给予有效量脂肪酸非潮红烟酸衍生物。
• METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
  申请人：Catabasis Pharmacauticals, Iinc.

  公开号：US20150344430A1

  公开（公告）日：2015-12-03

  The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.

  本发明涉及使用脂肪酸衍生物抑制前蛋白酶转化酶亚精氨酸/酶切割酶9 (PCSK9)来调节胆固醇的新方法；以及通过给予有效量的脂肪酸衍生物来治疗或预防代谢性疾病的新方法。本发明还涉及脂肪酸生物活性衍生物及其在治疗代谢性疾病中的应用。